Kristian Løvås
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kristian Løvås has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Eystein S. Husebye
3 shared publications- Anette Susanne Bøe Wolff
University of Bergen
1 shared publication B Bjorvatn
1 shared publication- Beate Skinningsrud
Department of Medical Genetics, Oslo University Hospital, Ullevål, N-0407 Oslo, Norway
1 shared publication Bjørn G. Nedrebø
1 shared publicationDag Undlien
1 shared publication
Latest Publications
- 1 December 2014
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 171 (6) , 743-750
CYP21A2 polymorphisms in patients with autoimmune Addison's disease, and linkage disequilibrium to HLA risk alleles
Objective Steroid 21-hydroxylase, encoded by CYP21A2, is the major autoantigen in autoimmune Addison's disease (AAD). CYP21A2 is located in the region of the HLA complex on chromosome 6p21.3, which harbours several risk alleles for AAD. The objective was to investigate whether CYP21A2 gene variants confer risk of AAD independently of other risk alleles in the HLA loci. Design DNA samples from 381 Norwegian patients with AAD and 340 healthy controls (HC) previously genotyped for the HLA-A, -B, -DRB1, and -DQB1 and MICA loci were used for genotyping of CYP21A2. Methods Genotyping of CYP21A2 was carried out by direct sequencing. Linkage of CYP21A2 to the HLA loci was assessed using UNPHASED version 3.0.10 and PHASE version 2.1. Results Heterozygotes of the single-nucleotide polymorphisms (SNPs) rs397515394, rs6467, rs6474, rs76565726 and rs6473 were detected significantly more frequently in AAD patients compared with HC (PHLA–DRB1 haplotypes. rs6472C protected against AAD (odds ratio=0.15, 95% CI (0.08–0.30), P=3.8×10−10). This SNP was not in an LD with HLA loci (P=0.02), but did not increase protection when considering the effect of HLA–DRB1 alleles. Mutations causing congenital adrenal hyperplasia were found in heterozygosity in Conclusion Genetic variants of CYP21A2 associated to AAD are in LD with the main AAD risk locus HLA-DRB1, and CYP21A2 does not constitute an independent susceptibility locus.
- 1 December 2014
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 171 (6) , 743-750
CYP21A2 polymorphisms in patients with autoimmune Addison's disease, and linkage disequilibrium to HLA risk alleles
Objective Steroid 21-hydroxylase, encoded by CYP21A2, is the major autoantigen in autoimmune Addison's disease (AAD). CYP21A2 is located in the region of the HLA complex on chromosome 6p21.3, which harbours several risk alleles for AAD. The objective was to investigate whether CYP21A2 gene variants confer risk of AAD independently of other risk alleles in the HLA loci. Design DNA samples from 381 Norwegian patients with AAD and 340 healthy controls (HC) previously genotyped for the HLA-A, -B, -DRB1, and -DQB1 and MICA loci were used for genotyping of CYP21A2. Methods Genotyping of CYP21A2 was carried out by direct sequencing. Linkage of CYP21A2 to the HLA loci was assessed using UNPHASED version 3.0.10 and PHASE version 2.1. Results Heterozygotes of the single-nucleotide polymorphisms (SNPs) rs397515394, rs6467, rs6474, rs76565726 and rs6473 were detected significantly more frequently in AAD patients compared with HC (PHLA–DRB1 haplotypes. rs6472C protected against AAD (odds ratio=0.15, 95% CI (0.08–0.30), P=3.8×10−10). This SNP was not in an LD with HLA loci (P=0.02), but did not increase protection when considering the effect of HLA–DRB1 alleles. Mutations causing congenital adrenal hyperplasia were found in heterozygosity in Conclusion Genetic variants of CYP21A2 associated to AAD are in LD with the main AAD risk locus HLA-DRB1, and CYP21A2 does not constitute an independent susceptibility locus.
- 1 June 2008
- Published by Bioscientifica in European Journal of Endocrinology
- Vol. 158 (6) , 939
Erratum: Continuous subcutaneous hydrocortisone infusion in Addison's disease.
The authors and the journal apologize for an error in the above paper which appeared in 157 (1) (109–112). In this paper on page 110, the hydrocortisone doses given in Fig. 1A were incorrect. The correct hydrocortisone doses were 0.5 (08–12 h), 0.2 (12–20 h), 0.05 (20–02 h) and 1.0 mg/m2 body surface area/hour (02–08 h).
- 1 June 2008
- Published by Bioscientifica in European Journal of Endocrinology
- Vol. 158 (6) , 939
Erratum: Continuous subcutaneous hydrocortisone infusion in Addison's disease.
The authors and the journal apologize for an error in the above paper which appeared in 157 (1) (109–112). In this paper on page 110, the hydrocortisone doses given in Fig. 1A were incorrect. The correct hydrocortisone doses were 0.5 (08–12 h), 0.2 (12–20 h), 0.05 (20–02 h) and 1.0 mg/m2 body surface area/hour (02–08 h).
- 1 April 2003
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 148 (4) , 449-456
Sleep disturbances in patients with Addison's disease
OBJECTIVE: The standard replacement therapy in Addison's disease does not restore normal nocturnal levels of the hormones of the hypothalamic-pituitary-adrenal axis. The aim of the study was to describe the prevalence and characteristics of sleep disturbances in patients with Addison's disease. METHODS: Sixty patients completed a self-administered sleep questionnaire and the Epworth Sleepiness Scale (ESS) questionnaire. Activity-based monitoring (actigraph recordings) and sleep diaries were obtained from eight patients. RESULTS: Thirty-four percent reported weekly sleep disturbances (difficulties falling asleep in 13%; repeated awakenings in 14%; early morning awakenings in 20%). The sleep need was 8.21 h (s.d. 1.34; range 6-14 h), and sleep onset latency was 29 min (s.d. 29, range 2-150 min). Forty percent of the patients were tired during daily activities more than once a week, but the scores of the ESS were 6.0 (s.d. 3.5), which is not higher than normal. The actigraph recordings showed higher sleep efficiency than the subjective recordings. CONCLUSION: We did not identify specific sleep disturbances which were characteristic for patients with Addison's disease. Patients with Addison's disease have increased daytime fatigue, but no more daytime sleepiness than normal.
- 1 April 2003
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 148 (4) , 449-456
Sleep disturbances in patients with Addison's disease
OBJECTIVE: The standard replacement therapy in Addison's disease does not restore normal nocturnal levels of the hormones of the hypothalamic-pituitary-adrenal axis. The aim of the study was to describe the prevalence and characteristics of sleep disturbances in patients with Addison's disease. METHODS: Sixty patients completed a self-administered sleep questionnaire and the Epworth Sleepiness Scale (ESS) questionnaire. Activity-based monitoring (actigraph recordings) and sleep diaries were obtained from eight patients. RESULTS: Thirty-four percent reported weekly sleep disturbances (difficulties falling asleep in 13%; repeated awakenings in 14%; early morning awakenings in 20%). The sleep need was 8.21 h (s.d. 1.34; range 6-14 h), and sleep onset latency was 29 min (s.d. 29, range 2-150 min). Forty percent of the patients were tired during daily activities more than once a week, but the scores of the ESS were 6.0 (s.d. 3.5), which is not higher than normal. The actigraph recordings showed higher sleep efficiency than the subjective recordings. CONCLUSION: We did not identify specific sleep disturbances which were characteristic for patients with Addison's disease. Patients with Addison's disease have increased daytime fatigue, but no more daytime sleepiness than normal.
- 1 March 2003
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 88 (3) , 1112-1118
Replacement of Dehydroepiandrosterone in Adrenal Failure: No Benefit for Subjective Health Status and Sexuality in a 9-Month, Randomized, Parallel Group Clinical Trial
The physiological role of dehydroepiandrosterone (DHEA) is not well understood, but studies suggest positive effects on subjective health and bone metabolism. We have conducted a clinical trial with DHEA replacement in adrenal failure with the primary aim of evaluating effects on subjective health status and sexuality. Thirty-nine women with adrenal failure were randomized to 9 months of treatment with 25 mg DHEA (n = 19) or placebo (n = 20). Treatment effects were assessed by validated questionnaires of subjective health and sexuality. DHEA replacement yielded a wide variation of effects on the subjective health scales, which were not different from the effects of placebo. Almost all patients receiving DHEA obtained normal androgen levels. Eighty-nine percent of the patients receiving DHEA experienced side-effects, in particular increased sweat odor and scalp itching. DHEA replacement did not significantly change the levels of blood lipids, IGF-I, and markers of bone metabolism. In conclusion, we do not find evidence of beneficial effects of DHEA on subjective health status and sexuality in adrenal failure. However, DHEA may be beneficial for subgroups of patients with adrenal failure, but these remain to be identified. Premenopausal androgen levels can be restored with 25 mg DHEA daily in most female patients, but side-effects are frequent.
- 1 March 2003
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 88 (3) , 1112-1118
Replacement of Dehydroepiandrosterone in Adrenal Failure: No Benefit for Subjective Health Status and Sexuality in a 9-Month, Randomized, Parallel Group Clinical Trial
The physiological role of dehydroepiandrosterone (DHEA) is not well understood, but studies suggest positive effects on subjective health and bone metabolism. We have conducted a clinical trial with DHEA replacement in adrenal failure with the primary aim of evaluating effects on subjective health status and sexuality. Thirty-nine women with adrenal failure were randomized to 9 months of treatment with 25 mg DHEA (n = 19) or placebo (n = 20). Treatment effects were assessed by validated questionnaires of subjective health and sexuality. DHEA replacement yielded a wide variation of effects on the subjective health scales, which were not different from the effects of placebo. Almost all patients receiving DHEA obtained normal androgen levels. Eighty-nine percent of the patients receiving DHEA experienced side-effects, in particular increased sweat odor and scalp itching. DHEA replacement did not significantly change the levels of blood lipids, IGF-I, and markers of bone metabolism. In conclusion, we do not find evidence of beneficial effects of DHEA on subjective health status and sexuality in adrenal failure. However, DHEA may be beneficial for subgroups of patients with adrenal failure, but these remain to be identified. Premenopausal androgen levels can be restored with 25 mg DHEA daily in most female patients, but side-effects are frequent.
- 19 June 2002
- Published by Wiley in Clinical Endocrinology
- Vol. 56 (6) , 787-791
High prevalence and increasing incidence of Addison's disease in western Norway
Summary: objective Estimates of the prevalence of Addison's disease in Caucasians have varied from 39 to 117 per million. We have carried out an epidemiological study to obtain a confident point prevalence estimate in the Norwegian population for the end of 1999, and to find out whether the incidence is changing.patients and methods The patients were identified by a search through registers of 10 hospitals and consultant endocrinologists serving a population of 916 000. The completeness of the list was tested by a survey of general practitioners in one district, and by the member list of the local Addison Association in another district.results We identified 128 patients with Addison's disease (59 men and 69 women), yielding a prevalence of 140 per million. Recorded mean incidence in the past decade was 0·62 per 100 000 per year. Fifty‐one patients (40%) had concomitant endocrine diseases. The aetiology was almost exclusively idiopathic or autoimmune.conclusions We found a higher prevalence of Addison's disease in western Norway than has previously been reported anywhere. Our findings support the hypothesis of a rising incidence of autoimmune adrenal insufficiency.
- 19 June 2002
- Published by Wiley in Clinical Endocrinology
- Vol. 56 (6) , 787-791
High prevalence and increasing incidence of Addison's disease in western Norway
Summary: objective Estimates of the prevalence of Addison's disease in Caucasians have varied from 39 to 117 per million. We have carried out an epidemiological study to obtain a confident point prevalence estimate in the Norwegian population for the end of 1999, and to find out whether the incidence is changing.patients and methods The patients were identified by a search through registers of 10 hospitals and consultant endocrinologists serving a population of 916 000. The completeness of the list was tested by a survey of general practitioners in one district, and by the member list of the local Addison Association in another district.results We identified 128 patients with Addison's disease (59 men and 69 women), yielding a prevalence of 140 per million. Recorded mean incidence in the past decade was 0·62 per 100 000 per year. Fifty‐one patients (40%) had concomitant endocrine diseases. The aetiology was almost exclusively idiopathic or autoimmune.conclusions We found a higher prevalence of Addison's disease in western Norway than has previously been reported anywhere. Our findings support the hypothesis of a rising incidence of autoimmune adrenal insufficiency.
- 26 May 2002
- Published by Wiley in Clinical Endocrinology
- Vol. 56 (5) , 581-588
Subjective health status in Norwegian patients with Addison’s disease*
Summary: objective Many patients with Addison’s disease have complaints that might be related to the disease or to its treatment. However, only a few studies have addressed the subjective health status of patients with adrenocortical failure. The aim of the present study was to assess the subjective health status with special emphasis on fatigue among patients with Addison’s disease.subjects, design and measurement In a postal survey, 79 patients with confirmed primary adrenal failure (Addison’s disease) completed the Short Form 36 (SF‐36) and the Fatigue questionnaires. The subjective health status in Addison’s disease was compared with normative data from the general population.results General health and vitality perception were most consistently impaired in the patients with Addison’s disease. The scores on physical functioning and role‐physical were low in women. Social functioning and role‐emotional scores were also lower than normal in the female patients, but this was confined to the patients with autoimmune polyendocrine syndromes. Patients with autoimmune polyendocrine syndromes tended to have lower scores than patients with solitary Addison’s disease. The level of fatigue was higher than normal for both men and women. Working disability at ages 18–67 years was 26%, compared with 10% in the corresponding general Norwegian population. The high working disability increased with age and was higher in subgroups with concomitant endocrine diseases. Most subjective health parameters were lower among the disabled compared to the patients in work.conclusions Patients with Addison’s disease under replacement therapy with cortisone acetate and fludrocortisone have reduced general health perception and vitality, and increased fatigue. Female patients reported reduced physical function, which might be due to adrenal androgen depletion. Mental health seems more influenced by concomitant endocrine diseases, but mental fatigue might be a specific feature in adrenal failure. The patient population is heterogeneous, with normal findings in a substantial proportion but markedly reduced subjective health status and working ability in many others. Thus, there might be potential for further refinement of replacement therapy.
- 26 May 2002
- Published by Wiley in Clinical Endocrinology
- Vol. 56 (5) , 581-588
Subjective health status in Norwegian patients with Addison’s disease*
Summary: objective Many patients with Addison’s disease have complaints that might be related to the disease or to its treatment. However, only a few studies have addressed the subjective health status of patients with adrenocortical failure. The aim of the present study was to assess the subjective health status with special emphasis on fatigue among patients with Addison’s disease.subjects, design and measurement In a postal survey, 79 patients with confirmed primary adrenal failure (Addison’s disease) completed the Short Form 36 (SF‐36) and the Fatigue questionnaires. The subjective health status in Addison’s disease was compared with normative data from the general population.results General health and vitality perception were most consistently impaired in the patients with Addison’s disease. The scores on physical functioning and role‐physical were low in women. Social functioning and role‐emotional scores were also lower than normal in the female patients, but this was confined to the patients with autoimmune polyendocrine syndromes. Patients with autoimmune polyendocrine syndromes tended to have lower scores than patients with solitary Addison’s disease. The level of fatigue was higher than normal for both men and women. Working disability at ages 18–67 years was 26%, compared with 10% in the corresponding general Norwegian population. The high working disability increased with age and was higher in subgroups with concomitant endocrine diseases. Most subjective health parameters were lower among the disabled compared to the patients in work.conclusions Patients with Addison’s disease under replacement therapy with cortisone acetate and fludrocortisone have reduced general health perception and vitality, and increased fatigue. Female patients reported reduced physical function, which might be due to adrenal androgen depletion. Mental health seems more influenced by concomitant endocrine diseases, but mental fatigue might be a specific feature in adrenal failure. The patient population is heterogeneous, with normal findings in a substantial proportion but markedly reduced subjective health status and working ability in many others. Thus, there might be potential for further refinement of replacement therapy.